SCHEMBL5354537

SCHEMBL5354537

Cc1ccc(C2(C(=O)NCCc3ccc(Cl)cc3Cl)CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.47
P2RX7 Q99572 1/20 0.47
CNR1 P21554 1/20 0.46
METAP1 P53582 1/20 0.46
HDAC4 P56524 1/20 0.46
NPSR1 Q6W5P4 2/20 0.46
LMNA P02545 1/20 0.46
IDO1 P14902 2/20 0.45
KCNH2 Q12809 1/20 0.45
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPT P10636 1/20 0.44
HTT P42858 1/20 0.43
PTGDR Q13258 1/20 0.43
KDM4E B2RXH2 1/20 0.43
GAA P10253 1/20 0.42
PLAAT3 P53816 1/20 0.42
PLAAT5 Q96KN8 1/20 0.42
PLAAT2 Q9NWW9 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4967506 0.87 CNR1 (0.56) METAP2P2RX7CNR1METAP1HDAC4
SCHEMBL5353140 0.86 SMN1; SMN2 (0.51) P2RX7CNR1HDAC4NPSR1LMNA
SCHEMBL5363274 0.85 HDAC4 (0.55) CNR1HDAC4NPSR1LMNASMN1; SMN2
SCHEMBL5352502 0.82 IDO1 (0.53) CNR1LMNAIDO1KCNH2HPGD
SCHEMBL5351946 0.82 CHRM2 (0.50) HDAC4NPSR1IDO1KCNH2SMN1; SMN2
SCHEMBL14491560 0.81 SMN1; SMN2 (0.54) CNR1HDAC4NPSR1LMNAIDO1
SCHEMBL5351676 0.78 HDAC4 (0.61) CNR1HDAC4SMN1; SMN2ALDH1A1MAPT
SCHEMBL5348970 0.77 SMN1; SMN2 (0.51) P2RX7CNR1HDAC4NPSR1LMNA
SCHEMBL5365092 0.77 SMN1; SMN2 (0.47) CNR1HDAC4NPSR1LMNAIDO1
SCHEMBL5357137 0.76 SMN1; SMN2 (0.49) NPSR1LMNAIDO1HPGDSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 METAP2 4524/4885P2RX7 930/4885CNR1 830/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.